It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Core Insights - Encompass Health Corporation (EHC) is experiencing growth due to increasing patient volumes, expansion initiatives, and a strong financial position [1] Financial Performance - EHC has a Zacks Rank of 2 (Buy) and its stock has increased by 16.6% over the past year, outperforming the industry growth of 7.2% [2] - The Zacks Consensus Estimate for EHC's 2025 earnings is $5.30 per share, reflecting a year-over-year increase of 19.6%, with revenues expected to reach $5.9 billion, indicating a 10.4% growth [5] - The 2026 earnings estimate is $5.81 per share, showing a 9.6% increase from 2025 [5] - The consensus estimate for 2026 revenues is projected at $6.5 billion, representing an 8.8% growth from the 2025 estimate [6] - EHC's earnings have consistently surpassed estimates, with an average surprise of 12.47% over the last four quarters [8] Growth Drivers - EHC's revenue growth is primarily driven by an expanding patient base in its inpatient rehabilitation hospitals, with a reported 10.6% revenue increase in the first nine months of 2025 compared to the same period in the previous year [9] - The company plans to add 150-200 beds in both 2026 and 2027, supported by a robust financial foundation, including $48.7 million in cash and cash equivalents as of September 30, 2025, and $829.6 million in operating cash flows for the first nine months of 2025, a 14.6% year-over-year increase [12] Expansion Initiatives - EHC is actively launching new inpatient rehabilitation hospitals, either independently or in collaboration with healthcare partners, enhancing its service capacity and nationwide footprint [10] - As of now, EHC operates 173 hospitals across 39 states and Puerto Rico, with the latest addition being the Rehabilitation Hospital of Lake Worth, opened in December [11]

Core Insights - The launch of the "Sanya-Prague" route marks China's first seventh-freedom passenger route, enhancing international air transport openness [1][3] - The new route aims to provide European travelers with a more direct and convenient travel option, potentially increasing international tourist traffic to Sanya [4] - Sanya's international aviation network has expanded significantly, with 41 international and regional routes now connecting 32 cities globally [4] Aviation Industry Impact - The introduction of the seventh-freedom route is a result of China's open policies in international air transport and the benefits from the Hainan Free Trade Port [3] - Sanya Phoenix International Airport has seen a record of over 21.849 million passenger trips, with international passenger volume increasing by 46.6% year-on-year [4] Economic and Market Development - The enhanced transportation accessibility has stimulated market vitality, leading to nearly 1,000 new business entities in sectors like tourism and high-tech industries since the Hainan Free Trade Port's special customs operations began [5] - During the first week of special customs operations, duty-free sales in Sanya reached 736 million yuan, a year-on-year increase of 48.2%, with tourist trips totaling 635,000, up 19% year-on-year [6]

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2]. Allegations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Surge - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit social-media-based promotion scheme that created a buying frenzy among retail investors through sensational but baseless claims [3]. - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit papers to the court by February 17, 2026, but participation is not required to be eligible for recovery [4]. - Individuals can choose to remain absent class members if they do not wish to take action [4]. Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [5].

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used off ...

NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers Charming Medical Ltd. (NASDAQ: MCTA) (“Charming”) that a federal securities class action has been filed on behalf of investors who purchased Integer between October 21, 2025 and November 12, 2025, inclusive (the “Class Period”). Investors have until February 17, 2026 to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION The filed complaint ...

MCDONALD, Tenn., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTCQB: AMROF) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value refractory and titanium alloy powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, is pleased to advise that it has received a Purchase Order from Titomic Limited (“Titomic”) in the amount of US$3.0 million for refractory alloy powders. The order has been received under the previous ...

Key Takeaways ECL closed the Ovivo Electronics deal, expanding its high-tech water platform.ECL adds Ovivo's ultrapure water expertise to enhance circular water solutions for chip manufacturing.The acquisition is set to more than double ECL's high-tech water business with strong long-term growth.Ecolab (ECL) recently closed its previously announced acquisition of Ovivo’s Electronics business, a fast-growing global provider of ultrapure water technologies used in semiconductor manufacturing. The deal meaning ...

Core Insights - Xcelerate, Inc. has made significant strategic adjustments in 2025 to align resources with long-term objectives, including the sale of its interest in ESN Group to strengthen its financial position and refocus on core missions [2][3] Financial Developments - The sale of ESN Group was an all-cash transaction that allowed Xcelerate to eliminate merchant finance debt associated with ESN, thereby improving its balance sheet [2] - The proceeds from the ESN sale, along with funds raised in a private placement, position the company to implement its AI-assisted patient portal program in early 2026 [3] Strategic Initiatives - Xcelerate is renewing its focus on AfiyaSasa Africa, LLC, aiming to launch an AI-assisted patient portal in Tanzania, which will connect patients in remote areas to clinicians [3][4] - The company is advancing its medical device patents, including a Surgical Tool with Targeting Guidance, and has filed additional applications in the EU and China [4] Communication and Engagement - To enhance transparency and shareholder engagement, Xcelerate is updating its corporate website and increasing its social media presence to share insights and progress updates [5] - A dedicated Investor Relations email will be established to streamline communication with shareholders [5] Future Outlook - In 2026, Xcelerate plans to carefully advance its key initiatives, particularly the AfiyaSasa platform, with a focus on testing technology in clinical settings and refining operations [6] - The company aims to maintain regular updates and transparent communication with shareholders as it progresses with AI-driven healthcare solutions [6]